Department of Biotechnology and Molecular Medicine, A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland.
Nucleic Acids Res. 2013 Mar 1;41(5):e61. doi: 10.1093/nar/gks1438. Epub 2012 Dec 28.
Integrating viral vectors are efficient gene transfer tools, but their integration patterns have been associated with genotoxicity and oncogenicity. The recent development of highly specific designer nucleases has enabled target DNA modification and site-specific gene insertion at desired genomic loci. However, a lack of consensus exists regarding a perfect genomic safe harbour (GSH) that would allow transgenes to be stably and reliably expressed without adversely affecting endogenous gene structure and function. Ribosomal DNA (rDNA) has many advantages as a GSH, but efficient means to target integration to this locus are currently lacking. We tested whether lentivirus vector integration can be directed to rDNA by using fusion proteins consisting of the Human Immunodeficiency Virus 1 (HIV-1) integrase (IN) and the homing endonuclease I-PpoI, which has natural cleavage sites in the rDNA. A point mutation (N119A) was introduced into I-PpoI to abolish unwanted DNA cleavage by the endonuclease. The vector-incorporated IN-I-PpoIN119A fusion protein targeted integration into rDNA significantly more than unmodified lentivirus vectors, with an efficiency of 2.7%. Our findings show that IN-fusion proteins can be used to modify the integration pattern of lentivirus vectors, and to package site-specific DNA-recognizing proteins into vectors to obtain safer transgene integration.
整合病毒载体是高效的基因转移工具,但它们的整合模式与遗传毒性和致癌性有关。最近,高度特异性的设计核酸酶的发展使得目标 DNA 的修饰和特定基因在所需的基因组位点的插入成为可能。然而,对于一个完美的基因组安全港(GSH),既能稳定可靠地表达转基因,又不会对内源性基因结构和功能产生不利影响,目前还没有达成共识。核糖体 DNA(rDNA)作为 GSH 有很多优点,但目前缺乏靶向整合到该基因座的有效方法。我们通过使用由人类免疫缺陷病毒 1(HIV-1)整合酶(IN)和归巢内切酶 I-PpoI 组成的融合蛋白来测试是否可以将慢病毒载体的整合导向 rDNA,I-PpoI 在 rDNA 中有天然的切割位点。引入一个点突变(N119A)到 I-PpoI 中,以消除内切酶的不必要的 DNA 切割。与未修饰的慢病毒载体相比,整合了 IN-I-PpoIN119A 融合蛋白的载体靶向 rDNA 的整合效率显著提高,达到 2.7%。我们的研究结果表明,IN 融合蛋白可用于修饰慢病毒载体的整合模式,并将特定的 DNA 识别蛋白包装到载体中,以获得更安全的转基因整合。